Castle Biosciences, Inc. (CSTL)
| Market Cap | 535.55M |
| Revenue (ttm) | 219.79M |
| Net Income (ttm) | -57.47M |
| Shares Out | 27.45M |
| EPS (ttm) | -2.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 177,998 |
| Open | 19.07 |
| Previous Close | 19.86 |
| Day's Range | 18.76 - 19.70 |
| 52-Week Range | 9.26 - 26.70 |
| Beta | 0.92 |
| Analysts | Strong Buy |
| Price Target | 32.11 (+64.58%) |
| Earnings Date | May 2, 2024 |
About CSTL
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with d... [Read more]
Financial Performance
In 2023, CSTL's revenue was $219.79 million, an increase of 60.38% compared to the previous year's $137.04 million. Losses were -$57.47 million, -14.41% less than in 2022.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price forecast is $32.11, which is an increase of 64.58% from the latest price.
News
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will release its financial results for the first quarter ended March 31, 2024, after the close of market on Thursday, May 2, 20...
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle recognizes the importance of Esophageal Cancer Awareness Month and is providing its support of key programs and initiatives thr...
Castle Biosciences' Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--For the second year in a row, Castle's chief financial officer, Frank Stokes, has been selected as a Top 25 CFO of Houston by TOP CFOs...
Presentations at EADO Highlight Potential Impact of Castle Biosciences' DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will share new data on its DecisionDx-Melanoma and DecisionDx-SCC tests at the 20th European Association of Dermato-Oncology (EADO) Congress...
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's executive management will present a company overview at the 23rd Annual Needham Virtual Healthcare Conference Tuesday, 4/9/24...
Castle Biosciences Announces Updates to its Board of Directors
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle today announced that Rodney Cotton has been appointed to its board of directors, effective immediately.
Castle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive Year
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announced it has received a Top Workplaces USA award for the third consecutive year.
Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced new data highlighting the performance of its DecisionDx-Melanoma test in predicting risk of SLN positivity in patients with melano...
Leading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation Therapy
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #40GEP--Expert consensus article in JCAD recommends framework including DecisionDx-SCC test for adjuvant radiation therapy decision-making in SCC patients...
New Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences' IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and Older
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announces new data highlighting its IDgenetix PGx test in guiding medication recommendations for patients 65+ with mental healt...
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences' executive management will present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTec...
Castle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual Meeting
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AAD2024--Castle Biosciences announces it will share data across its dermatologic portfolio of gene expression profile tests at the 2024 AAD Annual Meetin...
In Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk Subgroups
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences announced a new study in Dermatology and Therapy that analyzed the independent performance of its DecisionDx®-SCC test.
Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the...
Study Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition Staging
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AJCC8--Castle announced a study showing DecisionDx-Melanoma provided significantly better risk stratification than AJCC8 staging in stage I melanoma.
Castle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences today announced it will release its financial results for Q4 & year ended Dec. 31, 2023 after the close of market o...
New Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences' DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell Carcinoma
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--New study finds using Castle's DecisionDx-SCC test to guide ART decisions for SCC patients could result in substantial Medicare healthcare savings.
Castle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle will present new data across its dermatologic portfolio of GEP tests at the 2024 Winter Clinical Dermatology Conference - Hawaii.
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary...
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4).
Study Finds Nurse Practitioners and Physician Assistants Would Alter Patient Care Decisions Based on DecisionDx®-Melanoma Test Results
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced the publication of a new study that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma.
Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ASDS--Castle announced that data spanning its dermatologic portfolio of GEP tests was recently presented at the 2023 ASDS Annual Meeting.
Castle Biosciences Ranked Among the Top Workplaces in Houston by the Houston Chronicle for the Third Consecutive Year
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle Biosciences has been named a Houston Chronicle Top Workplace for the third year in a row.
Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announces data demonstrating the impact of IDgenetix® on medication response/remission rates in patients with major depressive ...
Castle Biosciences to Present at Upcoming Investor Conferences
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences' executive management will present a company overview at three investor conferences later this month.